These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 36134646)

  • 1. Calcium-channel blockers: Clinical outcome associations with reported pharmacogenetics variants in 32 000 patients.
    Türkmen D; Masoli JAH; Delgado J; Kuo CL; Bowden J; Melzer D; Pilling LC
    Br J Clin Pharmacol; 2023 Feb; 89(2):853-864. PubMed ID: 36134646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polygenic scores for cardiovascular risk factors improve estimation of clinical outcomes in CCB treatment compared to pharmacogenetic variants alone.
    Türkmen D; Bowden J; Masoli JAH; Delgado J; Kuo CL; Melzer D; Pilling LC
    Pharmacogenomics J; 2024 Apr; 24(3):12. PubMed ID: 38632276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RYR3 gene polymorphisms and cardiovascular disease outcomes in the context of antihypertensive treatment.
    Lynch AI; Irvin MR; Boerwinkle E; Davis BR; Vaughan LK; Ford CE; Aissani B; Eckfeldt JH; Arnett DK; Shrestha S
    Pharmacogenomics J; 2013 Aug; 13(4):330-4. PubMed ID: 22664477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antihypertensive pharmacogenetic effect of fibrinogen-beta variant -455G>A on cardiovascular disease, end-stage renal disease, and mortality: the GenHAT study.
    Lynch AI; Boerwinkle E; Davis BR; Ford CE; Eckfeldt JH; Leiendecker-Foster C; Arnett DK
    Pharmacogenet Genomics; 2009 Jun; 19(6):415-21. PubMed ID: 19352213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calcium Channel blockers are associated with reduced risk of Parkinson's disease in patients with hypertension: A population-based retrospective cohort study.
    Tseng YF; Lin HC; Chao JC; Hsu CY; Lin HL
    J Neurol Sci; 2021 May; 424():117412. PubMed ID: 33799214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CYP3A4*1G and CYP3A5*3 genetic polymorphisms alter the antihypertensive efficacy of amlodipine in patients with hypertension following renal transplantation
.
    Huang Y; Wen G; Lu Y; Wen J; Ji Y; Xing X; Li Y; Wen J; Yuan H
    Int J Clin Pharmacol Ther; 2017 Feb; 55(2):109-118. PubMed ID: 27841150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Actual impact of angiotensin II receptor blocker or calcium channel blocker monotherapy on renal function in real-world patients.
    Satoh M; Hirose T; Satoh H; Nakayama S; Obara T; Murakami T; Muroya T; Asayama K; Kikuya M; Mori T; Imai Y; Ohkubo T; Metoki H
    J Hypertens; 2022 Aug; 40(8):1564-1576. PubMed ID: 35792108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Long- and Intermediate-Acting Dihydropyridine Calcium Channel Blockers in Hypertension: A Systematic Review and Meta-Analysis of 18 Prospective, Randomized, Actively Controlled Trials.
    Chaugai S; Sherpa LY; Sepehry AA; Kerman SRJ; Arima H
    J Cardiovasc Pharmacol Ther; 2018 Sep; 23(5):433-445. PubMed ID: 29739234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetic association of the NPPA T2238C genetic variant with cardiovascular disease outcomes in patients with hypertension.
    Lynch AI; Boerwinkle E; Davis BR; Ford CE; Eckfeldt JH; Leiendecker-Foster C; Arnett DK
    JAMA; 2008 Jan; 299(3):296-307. PubMed ID: 18212314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.
    Xue H; Lu Z; Tang WL; Pang LW; Wang GM; Wong GW; Wright JM
    Cochrane Database Syst Rev; 2015 Jan; 1():CD008170. PubMed ID: 25577154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dihydropyridine Calcium Channel Blockers and Kidney Outcomes.
    Blum MF; Surapaneni A; Chang A; Inker LA; Chen TK; Appel LJ; Shin JI; Grams ME
    J Gen Intern Med; 2024 Apr; ():. PubMed ID: 38639831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic variation in the beta2 subunit of the voltage-gated calcium channel and pharmacogenetic association with adverse cardiovascular outcomes in the INternational VErapamil SR-Trandolapril STudy GENEtic Substudy (INVEST-GENES).
    Niu Y; Gong Y; Langaee TY; Davis HM; Elewa H; Beitelshees AL; Moss JI; Cooper-Dehoff RM; Pepine CJ; Johnson JA
    Circ Cardiovasc Genet; 2010 Dec; 3(6):548-55. PubMed ID: 21156931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic Kidney Disease Progression Risk in Patients With Diabetes Mellitus Using Dihydropyridine Calcium Channel Blockers: A Nationwide, Population-Based, Propensity Score Matching Cohort Study.
    Lin SY; Lin CL; Lin CC; Hsu WH; Hsu CY; Kao CH
    Front Pharmacol; 2022; 13():786203. PubMed ID: 35355728
    [No Abstract]   [Full Text] [Related]  

  • 14. Calcium channel blockers as initial therapeutic agents in hypertension: relationship to incident heart failure.
    Shields DL
    Biol Res Nurs; 2014 Jul; 16(3):266-77. PubMed ID: 23864228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HYT-hypertension in Turkey: a cross-sectional survey on blood pressure control with calcium channel blockers alone or combined with other antihypertensive drugs.
    Seravalle G; Koylan N; Nalbantgil I; Caglar N; Quarti-Trevano F; Makel W; Grassi G; Fici F
    High Blood Press Cardiovasc Prev; 2015 Jun; 22(2):165-72. PubMed ID: 25900022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between cardiovascular outcomes and antihypertensive drug treatment in older women.
    Wassertheil-Smoller S; Psaty B; Greenland P; Oberman A; Kotchen T; Mouton C; Black H; Aragaki A; Trevisan M
    JAMA; 2004 Dec; 292(23):2849-59. PubMed ID: 15598916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
    Davis BR; Piller LB; Cutler JA; Furberg C; Dunn K; Franklin S; Goff D; Leenen F; Mohiuddin S; Papademetriou V; Proschan M; Ellsworth A; Golden J; Colon P; Crow R;
    Circulation; 2006 May; 113(18):2201-10. PubMed ID: 16651474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of genes implicated in cardiovascular disease on blood pressure response to treatment among treatment-naive hypertensive African Americans in the GenHAT study.
    Do AN; Lynch AI; Claas SA; Boerwinkle E; Davis BR; Ford CE; Eckfeldt JH; Tiwari HK; Arnett DK; Irvin MR
    J Hum Hypertens; 2016 Sep; 30(9):549-54. PubMed ID: 26791477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calcium channel blockers versus other classes of drugs for hypertension.
    Zhu J; Chen N; Zhou M; Guo J; Zhu C; Zhou J; Ma M; He L
    Cochrane Database Syst Rev; 2022 Jan; 1(1):CD003654. PubMed ID: 35000192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calcium channel blockers versus other classes of drugs for hypertension.
    Zhu J; Chen N; Zhou M; Guo J; Zhu C; Zhou J; Ma M; He L
    Cochrane Database Syst Rev; 2021 Oct; 10(10):CD003654. PubMed ID: 34657281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.